Key Points
- Director Brian Cherry purchased 104,166 ATRA shares at an average $9.60 per share, investing approximately $1 million and increasing his ownership by 167.15% to 166,486 shares.
- Atara Biotherapeutics shares opened at $9.76, with a market capitalization of about $98 million. The company met quarterly EPS expectations at a loss of $0.32 per share, while revenue of $0.63 million exceeded estimates.
- Analyst sentiment is mixed but averages to a “Moderate Buy”, with a consensus price target of $9.50; institutional investors own approximately 70.9% of the company.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) Director Brian Cherry bought 104,166 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $9.60 per share, with a total value of $999,993.60. Following the completion of the transaction, the director owned 166,486 shares in the company, valued at approximately $1,598,265.60. This trade represents a 167.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Atara Biotherapeutics Stock Up 2.4%
ATRA opened at $9.76 on Friday. The firm has a market cap of $97.99 million, a price-to-earnings ratio of -8.27 and a beta of 0.10. Atara Biotherapeutics, Inc. has a 52 week low of $3.92 and a 52 week high of $19.15. The business's 50 day moving average is $9.14 and its two-hundred day moving average is $7.75.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, meeting the consensus estimate of ($0.32). The business had revenue of $0.63 million during the quarter, compared to the consensus estimate of $0.55 million. Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 269.42%. Equities analysts expect that Atara Biotherapeutics, Inc. will post -0.22 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on ATRA shares. Weiss Ratings upgraded shares of Atara Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Freedom Capital raised Atara Biotherapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, May 18th. TD Cowen raised Atara Biotherapeutics to a "strong-buy" rating in a report on Monday, August 24th. Wall Street Zen upgraded Atara Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, August 16th. Finally, Canaccord Genuity Group set a $13.00 target price on Atara Biotherapeutics and gave the company a "buy" rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $9.50.
Read Our Latest Report on ATRA
Institutional Trading of Atara Biotherapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock worth $464,000 after purchasing an additional 1,457 shares in the last quarter. Quadrature Capital Ltd lifted its stake in Atara Biotherapeutics by 22.8% in the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company's stock valued at $368,000 after buying an additional 3,779 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Atara Biotherapeutics during the 2nd quarter valued at $31,000. Dimensional Fund Advisors LP acquired a new stake in Atara Biotherapeutics during the 4th quarter valued at $181,000. Finally, Renaissance Technologies LLC increased its position in Atara Biotherapeutics by 58.6% during the fourth quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company's stock worth $543,000 after buying an additional 11,104 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company's stock.
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
